Provided by Tiger Trade Technology Pte. Ltd.

Merck

144.71
-2.8200-1.91%
Post-market: 144.710.00000.00%17:28 EDT
Volume:7.50M
Turnover:1.09B
Market Cap:357.02B
PE:113.69
High:148.00
Open:147.94
Low:144.10
Close:147.53
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.95
T/O Rate:0.30%
Dividend:3.32
Dividend Rate:2.29%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.51
PE(LYR):19.88

Loading ...

Movement Alert|Merck Rises 8.75% in Regular Trading, Phase III Melanoma Vaccine Trial Meets Primary Endpoint

Market Focus
·
Aug 19

Sector Update: Healthcare

MT Newswires Live
·
Aug 19

Biotech Stocks Jump Premarket After Moderna's Melanoma Vaccine with Merck Succeeds in Large Trial

THOMSON REUTERS
·
Aug 19

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn

Dow Jones
·
Aug 19

Stocks to Watch: Oracle, SK Hynix, Moderna, Unitree

Dow Jones
·
Aug 19

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 19

U.S. Stocks on the MOVE-Estee Lauder, Target, Analog Devices

Reuters
·
Aug 19

Merck, Moderna Say Potential Melanoma Therapy Shows 'Statistically Significant Improvement' in Late-Stage Trial

MT Newswires Live
·
Aug 19

Bond Yields, Persian Gulf Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off

MT Newswires Live
·
Aug 19

Moderna Stock Surges 70%, Merck Rises 6%. at Last, a Successful Cancer Vaccine.

Dow Jones
·
Aug 19

Moderna and Merck Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Moderna Vaccine Cuts Recurrence and Spread of High-Risk Melanoma, Raising New Treatment Hope

Reuters
·
Aug 19

Movement Alert|Merck Rises 5.41% in Pre-Market Trading, Melanoma Vaccine Phase 3 Trial Meets Primary Endpoint

Market Focus
·
Aug 19

Merck Shares Rise 1.9% Premarket

THOMSON REUTERS
·
Aug 19

Merck, Moderna Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Merck: Safety Profiles of Intismeran and Keytruda in Trial were Consistent with Prior Reported Studies for the Combination

THOMSON REUTERS
·
Aug 19

Merck: Phase 3 Interpath-001 Trial of Intismeran Autogene Plus Keytruda Met Primary Endpoint of Recurrence Free Survival

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Announce Positive Results from Phase 3 Interpath-001 Trial for Patients with Completely Resected Stage Iib-Iv Melanoma

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Will Engage with Regulators on Filing Submissions for Intismeran Autogene in Combination with Keytruda

THOMSON REUTERS
·
Aug 19

The Key to Pharma M&A: Never Shopping Hungry - Heard on the Street

Dow Jones
·
Aug 19